Metabolic/Biochemical

88-90%
Strong

for inborn errors of metabolism, newborn screening confirmation, and leukodystrophies with exome sequencing

System Profile

Yield Comparison

Clinical Dimensions

  • Hypoglycemia
  • Acidosis
  • Metabolic crises with illness or fasting
  • Vomiting after high-protein meals
  • Lethargy
  • Urea cycle disorders
  • FAODs
  • Organic acidemias
  • Galactosemia
  • MSUD
  • Mitochondrial diseases
  • Peroxisomal disorders
  • Glycogen storage diseases
  • Kussmaul breathing
  • Hepatomegaly
  • Unusual body odor
  • Hypotonia with intermittent crisis
  • Abnormal fat distribution
  • Dysmorphic features typical of metabolic syndromes
  • Lethargy with fasting
  • Vomiting during illness
  • Coma-like episodes
  • Seizures triggered by high-protein intake
  • Intolerance to exercise
  • Unexplained hypoglycemia
  • Elevated ammonia
  • Anion-gap metabolic acidosis
  • Ketosis/hypoketosis
  • Abnormal plasma amino acids
  • Abnormal urine organic acids
  • Abnormal acylcarnitine profile
  • Low carnitine
  • Abnormal lactate/pyruvate ratio
  • Positive newborn screen markers
  • MRI with symmetric basal ganglia lesions
  • White matter abnormalities
  • MR spectroscopy showing lactate
  • Concurrent hepatic or renal cystic changes
  • Skeletal rickets changes
  • Plasma amino acids
  • Urine organic acids
  • Acylcarnitine profile
  • Lactate/pyruvate ratio
  • Enzyme assays
  • Fibroblast metabolic studies
  • Newborn screen confirmatory tests
  • Carnitine
  • Riboflavin
  • Thiamine
  • Biotin
  • Sodium benzoate
  • Bicitra
  • Continuous or emergency dextrose infusions
  • Tailored metabolic supplements
  • Metabolic decompensation triggered by high-protein formula or intravenous feeds
  • Intolerance to standard IV solutions
  • Adverse responses to fasting or common IV meds
  • G-tube placement for metabolic feeding
  • Central line placement for metabolic infusions
  • Biopsies (liver, muscle, skin) for enzyme or mitochondrial studies
  • Metabolic diet therapy (protein/fat restriction, special formulas)
  • Sick-day emergency plans
  • Caregiver training for decompensation management
  • Pumps and feeding devices for continuous metabolic formulas
  • Home glucose/ketone monitors
  • Metabolic genetics teams
  • Biochemical genetics
  • Multidisciplinary metabolic clinics
  • Recurrent hospitalizations requiring metabolic consults
  • Geneticist following long-term
  • Known metabolic disorders
  • Neonatal deaths of unknown cause
  • Recurrent metabolic crises
  • Unexplained SIDS
  • Consanguinity
  • Multiple siblings with similar episodes
  • No starvation, fad dieting, or food insecurity explaining hypoglycemia or metabolic crises
  • Metabolic decompensation tied to illness rather than environment
  • Abnormal newborn metabolic screen
  • Persistent metabolic acidosis
  • Hyperammonemia
  • Hypoglycemia
  • Vomiting or lethargy within first days/weeks

Red Flag Combinations

Clinical patterns that should prompt consideration of genetic testing

Hypoglycemia + hyperammonemia
Vomiting + metabolic acidosis
Exercise intolerance + rhabdomyolysis
Recurrent decompensation with illness or fasting

Screening Decision Pathway

When to consider genetic testing for metabolic/biochemical presentations

        graph TD
          START["Patient Presents with\nMetabolic/Biochemical Concerns"] --> SCREEN{"Screen for\nRed Flags"}
          
          SCREEN --> RF1["Positive newborn metabolic screening"]
          
          SCREEN --> RF2["Abnormal glucose/ketone strips"]
          
          SCREEN --> RF3["Abnormal lactate or ammonia on routine lab screen"]
          
          SCREEN --> RF4["Tandem MS findings"]
          
          
          RF1 --> EVAL{"Multiple\nFlags Present?"}
          
          RF2 --> EVAL{"Multiple\nFlags Present?"}
          
          RF3 --> EVAL{"Multiple\nFlags Present?"}
          
          RF4 --> EVAL{"Multiple\nFlags Present?"}
          
          EVAL -->|Yes| TEST["Order Genetic Testing\n(ES/GS)"]
          EVAL -->|No| MONITOR["Continue Monitoring\nRe-evaluate if New Findings"]
          TEST --> DX["Molecular Diagnosis\n88-90% yield"]
          style TEST fill:#dcfce7,stroke:#16a34a,color:#14532d
          style DX fill:#bbf7d0,stroke:#16a34a,color:#14532d
          style MONITOR fill:#fef3c7,stroke:#d97706,color:#92400e
        

Screening Red Flags

Findings on routine screening that may indicate genetic etiology

  • Positive newborn metabolic screening
  • Abnormal glucose/ketone strips
  • Abnormal lactate or ammonia on routine lab screen
  • Tandem MS findings

Exome / Genome Sequencing Indications

Clinical scenarios supporting ES/GS as a diagnostic approach

  • Any pattern of recurrent metabolic crises
  • Unexplained lactic acidosis
  • Hyperammonemia
  • Hypoglycemia
  • Multisystem involvement where targeted metabolic testing is inconclusive

Key Evidence

Published studies supporting genetic testing for metabolic/biochemical conditions

Study Year Type Sample Yield Key Finding
Genetic diagnosis by whole exome sequencing is complemented ... 2018 Cohort None 10-35% RNA-seq transcriptomics provides 10-35% additional diagnostic yield beyond WES a...
Effectiveness of Whole Exome Sequencing Diagnosis in the Cli... 2018 Review None 16-68% WES diagnostic yield ranges 16-68% across IEM and neurogenetic disorder cohorts ...
A Comprehensive Multiplex PCR Based Exome-Sequencing Assay f... 2019 Cohort None 89% 89% concordance between PEARS enzymatic assay and molecular testing for PKU in 8...
Genomic Sequencing for Newborn Screening: Results of the NC ... 2020 Cohort None 88% 88% (15/17) of metabolic disorders confirmed by exome sequencing in NC NEXUS new...
Exome Sequencing for Prenatal Diagnosis in Nonimmune Hydrops... 2020 Cohort 127 29% Exome sequencing identified a genetic diagnosis in 29% of NIHF cases after stand...
Clinical exome sequencing as a first-tier test for the diagn... 2021 Cohort 128 55% CES as first-tier test achieved 55% overall diagnostic yield in 128 pediatric pa...
100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Ca... 2021 Cohort 2183 25% 25% diagnostic yield in 2183 rare disease families; monogenic disorders 35% vs c...
Next-Generation Sequencing for Inborn Errors of Metabolism i... 2022 Cohort None 64.3% NGS achieved 64.3% diagnostic yield for IEM in Lebanese population; WES yielded ...
Updated: 2026-02-25 Curated by: human Status: human reviewed